<u></u>	<u> </u>	
i.	Application No.	Applicant(s)
* A	09/825,293	FARWICK ET AL.
Notice of Allowability	Examiner	Art Unit
	Christian L Fronda	1652
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
1. This communication is responsive to <u>AMENDMENT PURSUANT TO 37 C.F.R. 1.116 dated April 13, 2004</u> .		
2. The allowed claim(s) is/are <u>20-22,27,32-36 and 40-45</u> .		
3. The drawings filed on <u>04 April 2001</u> are accepted by the Examiner.		
4.   Acknowledgment is made of a claim for foreign priority una  a)   All b)   Some* c)   None of the:  1.   Certified copies of the priority documents have	e been received.	
<ul> <li>2.  Certified copies of the priority documents have been received in Application No</li> <li>3.  Copies of the certified copies of the priority documents have been received in this national stage application from the</li> </ul>		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
5. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
6. CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.		
(a) $\square$ including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached		
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
<ol> <li>DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.</li> </ol>		
Attachment(s)  1. Notice of References Cited (PTO-892)	5. Notice of Informal	Patent Application (PTO-152)
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. ☐ Interview Summar Paper No./Mail D	y (PTO-413),
3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date		
4. ☐ Examiner's Comment Regarding Requirement for Deposit	8. 🛭 Examiner's Statem	nent of Reasons for Allowance
of Biological Material	9.	

Art Unit: 1652

## **EXAMINER'S AMENDMENT**

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Thomas Cawley on May 12, 2004.

- 2. The application has been amended as follows:
- Replace claim 21 with the following:

  "An isolated polynucleotide consisting of nucleotides 252-1673 of SEQ ID NO: 1 or fragment thereof which encodes a transcription regulator protein that inhibits lysine production in a bacterial cell."
- Cancel claims 37 and 38.
- Replace claim 40 with the following:
  - "An isolated polynucleotide which hybridizes under stringent conditions to the complement of SEQ ID NO: 1 and encodes a transcription regulator protein that inhibits lysine production in a bacterial cell, wherein said stringent conditions comprise washing in 0.5X SSC at a temperature of 68°C."
- Replace claim 41 with the following:
  - "An isolated polynucleotide which hybridizes under stringent conditions to the complement of SEQ ID NO: 1 and encodes a transcription regulator protein that inhibits lysine production in a bacterial cell, wherein said stringent conditions comprise washing in 0.1X SSC at a temperature of 68°C."
- In claim 44, line 1, delete the word "essentially".
- 3. Claims 20-22, 27, 32-36, and 40-45 are allowed.
- 4. The following is an examiner's statement of reasons for allowance:

Applicants' novel and unobvious invention is directed toward an isolated polynucleotide encoding a transcription regulator protein that inhibits lysine production in a bacterial cell, a vector comprising said isolated polynucleotide, and a host cell transformed with said vector. The

Art Unit: 1652

prior art neither teaches nor suggests an isolated polynucleotide having a nucleotide sequence of SEQ ID NO: 1 or an isolated polynucleotide encoding a transcription regulator protein that inhibits lysine production in a bacterial cell having an amino acid sequence of SEQ ID NO:2.

- 5. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christian L Fronda whose telephone number is (571)272-0929. The examiner can normally be reached Monday-Friday between 9:00AM 5:00PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura N Achutamurthy can be reached on (571)272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

**CLF** 

SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600